Patent Assignment
Reel/Frame 068510/0363
Security Interest
Recorded: 2024-08-07
Pages: 201
Assignor
ARROWHEAD PHARMACEUTICALS, INC.
Executed: 2024-08-07
Assignee
SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT
2100 MCKINNEY AVENUE, SUITE 1500, DALLAS, TEXAS, 75201
Covered Properties
(288)
Polyconjugates for in Vivo Delivery of Polynucleotides
Polyconjugates for In Vivo Delivery of Polynucleotides
Membrane Active Heteropolymers
Reversibly Masked Polymers
Endosomolytic Poly(Acrylate) Polymers
Intravenous Delivery of Polynucleotides to Cells in Mammalian Limb
Reversible Attachment of a Membrane Active Polymer to a Polynucleotide
Polyvinylethers for Delivery of Polynucleotides to Mammalian Cells
Membrane Active Heteropolymers
Compositions and Methods for Drug Delivery Using Ph Sensitive Molecules
Compositions for Targeted Delivery of Sirna
Compositions for Targeted Delivery of siRNA
Compositions for Targeted Delivery of siRNA
Compositions for Targeted Delivery of siRNA
Compositions and Methods for Inhibiting Expression of RRM2 Genes
Compositions and Methods for Inhibiting Expression of RRM2 Genes
Compositions and Methods for Inhibiting Expression of RRM2 Genes
Compositions and Methods for Inhibiting Expression of RRM2 Genes
Peptide-Based In Vivo siRNA Delivery System
Peptide-Based In Vivo siRNA Delivery System
Peptide-Based In Vivo siRNA Delivery System
Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for Sirna
Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA
In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages
In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages
Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus
Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus
Patent:
48,345 →
Application:
15/241,733 →
Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus
Application:
17/031,826 →
Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus
Application:
18/653,842 →
Disubstituted Maleic Anhydrides with Altered Kinetics of Ring Closure
Disubstituted Maleic Anhydrides with Altered Kinetics of Ring Closure
Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery
Poly(Acrylate) Polymers for in Vivo Nucleic Acid Delivery
Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo
Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin
Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin
Compositions and Methods for Inhibiting Gene Expression of Alpha-1 Antitrypsin
Compositions and Methods for Inhibiting Gene Expression of Factor Xii
Compositions and Methods for Inhibiting Gene Expression of Factor XII
Compositions and Methods for Inhibiting Gene Expression of Factor XII
Compositions and Methods for Inhibiting Gene Expression of LPA
Compositions and Methods for Inhibiting Gene Expression of LPA
Compositions and Methods for Inhibiting Gene Expression of Lpa
Application:
16/867,925 →
Publication:
US US20200263179A1
Compositions and Methods for Inhibiting Gene Expression of Lpa
Application:
18/745,289 →
Publication:
US US20250115907A1
Compositions and Methods for Inhibiting Gene Expression of HIF2ALPHA
Compositions and Methods for Inhibiting Gene Expression of Hif2alpha
Compositions and Methods for Inhibiting Gene Expression of Hif2alpha
Biologically Cleavable Tetrapeptide Linking Agents
Disulfide-Containing Alkyne Linking Agents
Disulfide-Containing Alkyne Linking Agents
RNAi Therapy for Hepatitis B Virus Infection
RNAi Therapy for Hepatitis B Virus Infection
Rnai Therapy for Hepatitis B Virus Infection
Rnai Therapy for Hepatitis B Virus Infection
Application:
18/069,490 →
Publication:
US US20230355654A1
Alpha-V Beta-6 Integrin Ligands and Uses Thereof
Alpha-V Beta-6 Integrin Ligands and Uses Thereof
Targeting Ligands
Targeting Ligands
Targeting Ligands
Application:
17/351,169 →
Publication:
US US20220033817A1
5'-Cyclo-Phosphonate Modified Nucleotides
5'-Cyclo-Phosphonate Modified Nucleotides
Rnai Agents for Hepatitis B Virus Infection
Rnai Agents for Hepatitis B Virus Infection
Rnai Agents for Hepatitis B Virus Infection
Rnai Agents for Hepatitis B Virus Infection
Application:
18/074,268 →
Publication:
US US20230355651A1
Compositions and Methods for Inhibition of Factor XII Gene Expression
Application:
18/408,970 →
Compositions and Methods for Inhibition of Factor XII Gene Expression
Application:
18/678,687 →
Targeting Ligands For Therapeutic Compounds
Targeting Ligands For Therapeutic Compounds
Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use
Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use
Alpha-1 Antitrypsin (Aat) Rnai Agents, Compositions Including Aat Rnai Agents, and Methods of Use
Alpha-1 Antitrypsin (Aat) Rnai Agents, Compositions Including Aat Rnai Agents, and Methods of Use
Application:
18/530,795 →
Publication:
US US20240141351A1
RNAi Agents And Compositions for Inhibiting Expression of Asialoglycoprotein Receptor 1
RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)
RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)
RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)
RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use
Rnai Agents for Inhibiting Expression of Alpha-Enac and Methods of Use
Integrin Targeting Ligands and Uses Thereof
RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use
RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use
Application:
17/231,479 →
Publication:
US US20210238602A1
RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use
Integrin Ligands and Uses Thereof
Integrin Ligands and Uses Thereof
Application:
18/160,114 →
Publication:
US US20240076270A1
RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use
Trialkyne Linking Agents and Methods of Use
Trialkyne Linking Agents and Methods of Use
Application:
18/773,657 →
Publication:
US US20250092072A1
RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use
RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use
RNAi Agents for Inhibiting Expression of PNPLA3, Pharmaceutical Compositions Thereof, and Methods of Use
Application:
18/748,261 →
Publication:
US US20250034577A1
Rnai Agents for Hepatitis B Virus Infection
Application:
17/396,378 →
Publication:
US US20210395745A1
RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use
Application:
63/308,289 →
RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use
Application:
63/345,654 →
RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use
Application:
18/048,577 →
Publication:
US US20230265437A1
Methods for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd)
Integrin Targeting Ligands and Uses Thereof
RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use
RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use
RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use
Application:
18/181,311 →
Publication:
US US20230416737A1
Methods For The Treatment Of APOC3-Related Diseases And Disorders
Application:
17/592,182 →
Publication:
US US20220152079A1
Skeletal Muscle Delivery Platforms and Methods of Use
Application:
18/181,335 →
Publication:
US US20240175019A1
Lipid Conjugates for the Delivery of Therapeutic Agents
Application:
18/178,242 →
Publication:
US US20230226193A1
RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use
Skeletal Muscle Delivery Platforms and Methods of Use Thereof
Application:
18/178,179 →
Publication:
US US20230265429A1
Methods for the Reduction of Z-Aat Protein Levels
Application:
18/026,340 →
Publication:
US US20230348905A1
Integrin Targeting Ligands and Uses Thereof
Application:
18/181,340 →
Publication:
US US20230407313A1
RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
63/381,200 →
RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
63/486,944 →
RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
63/493,564 →
RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of Use
RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use
Application:
63/352,454 →
RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use
Application:
63/495,517 →
RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
63/323,430 →
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
18/046,108 →
Publication:
US US20230139166A1
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
RNAi Agents for Inhibiting Expression of Ataxin-2 (ATXN2), Compositions Thereof, and Methods of Use
Application:
63/490,866 →
RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use
Application:
63/306,045 →
RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use
Application:
63/376,297 →
Treatment of a Non-Alcoholic Fatty Liver Disease
Application:
63/329,081 →
Treatment of a Non-Alcoholic Fatty Liver Disease
Application:
63/401,858 →
Subcutaneous Delivery of RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products
Application:
63/322,609 →
Subcutaneous Delivery of RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products
Application:
63/484,557 →
Lipid Conjugates for the Delivery of Therapeutic Agents to Cns Tissue
Application:
63/352,485 →
Lipid Conjugates for the Delivery of Therapeutic Agents to Cns Tissue
Application:
63/495,505 →
RNAi Agents for Inhibiting Expression of Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
63/487,899 →
Methods For The Treatment Of ANGPTL3-Related Diseases And Disorders
Application:
63/373,175 →
Methods For The Treatment Of ANGPTL3-Related Diseases And Disorders
Application:
63/376,302 →
Methods For The Treatment Of ANGPTL3-Related Diseases And Disorders
Application:
63/382,916 →
Methods For The Treatment Of ANGPTL3-Related Diseases And Disorders
Application:
63/492,548 →
Methods For The Treatment Of ANGPTL3-Related Diseases And Disorders
Application:
63/506,910 →
RNAi Agents for Inhibiting Expression of DM1 Protein Kinase (DMPK) Compositions Thereof, And Methods of Use
Application:
63/380,171 →
RNAi Agents for Inhibiting Expression of DM1 Protein Kinase (DMPK) Compositions Thereof, And Methods of Use
Application:
63/584,283 →
RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
63/579,708 →
RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
63/618,015 →
RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
63/634,173 →
Lipid Conjugates for the Delivery of Therapeutic Agents to Adipose Tissue
Application:
63/478,795 →
Lipid Conjugates for the Delivery of Therapeutic Agents to Adipose Tissue
Application:
63/612,901 →
RNAi Agents for Inhibiting Influenza Viral Gene Expression, Compositions Thereof, and Methods of Use
Application:
63/479,859 →
RNAi Agents for Inhibiting Influenza Viral Gene Expression, Compositions Thereof, and Methods of Use
Application:
63/488,062 →
RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of Use
Application:
63/499,065 →
RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of Use
Application:
63/596,336 →
RNAi Agents for Inhibiting Expression of Mitochondrial Amidoxime Reducing Component 1 (MARC1), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
63/490,694 →
RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
63/491,505 →
RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of Use
Application:
63/566,013 →
RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of Use
Belt Reactor Manufacturing Process for Oligomer Synthesis
Application:
63/482,675 →
Hepatic Delivery Platforms For Multimeric RNAi Agent Conjugates and Methods of Use Thereof
Application:
63/505,407 →
Hepatic Delivery Platforms For Multimeric RNAi Agent Conjugates and Methods of Use Thereof
Application:
63/559,701 →
RNAi Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (TSLP), Compositions Thereof, and Methods of Use
Application:
63/485,081 →
RNAi Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (TSLP), Compositions Thereof, and Methods of Use
Application:
63/516,300 →
RNAi Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (TSLP), Compositions Thereof, and Methods of Use
Application:
63/625,543 →
Metabolically Stabilized Carbohydrate Targeting Ligands For Oligonucleotide Conjugates
Application:
63/505,414 →
Metabolically Stabilized Carbohydrate Targeting Ligands For Oligonucleotide Conjugates
Application:
63/559,728 →
Oligonucleotide Synthesis Methods
Application:
63/519,443 →
Anti-Transferrin Receptor Antibody Conjugates and Methods of Treating CNS Diseases
Application:
63/624,417 →
Anti-Transferrin Receptor Antibody Conjugates and Methods of Treating Cns Diseases
Application:
63/573,151 →
Anti-Transferrin Receptor Antibody Conjugates and Methods of Treating Cns Diseases
Application:
63/662,243 →
Process for Preparation of Targeting Ligands
Application:
18/291,170 →
Publication:
US US20250289843A1
RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use
Application:
63/612,531 →
RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use
Application:
63/634,860 →
RNAi Agents for Inhibiting Expression of Myocilin (MYOC), Compositions Thereof, and Methods of Use
Application:
63/639,045 →
RNAi Agents for Dual Inhibition of Expression of Apolipoprotein C-III (APOC3) and Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Compositions Thereof, and Methods of Use
Application:
63/559,682 →
RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use
Application:
63/572,349 →
RNAi Agents for Inhibiting Expression of Huntingtin (HTT), Compositions Thereof, and Methods of Use
Application:
63/662,268 →
RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use
Application:
63/572,350 →
RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use
Application:
63/573,135 →
Linkers and Methods for the Synthesis of Anti-Transferrin Receptor Antibody Conjugates
Application:
63/662,272 →
Treatment of Neurological Disorders by Dsrna Administration
Treatment of Neurological Disorders by Dsrna Administration
Rnai Inhibition of Alpha-Enac Expression
RNAi Inhibition of Alpha-ENaC Expression
Rnai Inhibition of Alpha-Enac Expression
Rnai Inhibition of Alpha-Enac Expression
Rnai Inhibition of Alpha-Enac Expression
RNAi Inhibition of Alpha-ENaC Expression
RNAi Inhibition of Alpha-ENaC Expression
RNAi Inhibition of Alpha-ENaC Expression
RNAi Inhibition of Alpha-ENaC Expression
dsRNA For Treating Viral Infection
dsRNA For Treating Viral Infection
dsRNA For Treating Viral Infection
Organic Compositions to Treat HSF1-Related Diseases
Organic Compositions to Treat HSF1-Related Diseases
Organic Compositions to Treat HSF1-Related Diseases
Organic Compositions to Treat HSF1-Related Diseases
Organic Compositions to Treat HSF1-Related Diseases
Organic Compositions to Treat HSF1-Related Diseases
Organic Compositions to Treat HSF1-Related Diseases
Organic Compositions to Treat HSF1-Related Diseases
Organic Compositions to Treat Beta-ENaC-Related Diseases
ORGANIC COMPOSITIONS TO TREAT Beta-ENaC-RELATED DISEASES
Organic Compositions to Treat Beta-ENaC-Related diseases
Organic Compositions to Treat Beta-ENaC-Related Diseases
Organic Compositions to Treat Beta-Enac-Related Diseases
Organic Compositions to Treat Beta-ENaC-Related Diseases
Organic Compositions to Treat Beta-Catenin-Related Diseases
Organic Compositions to Treat Beta-Catenin-Related Diseases
Application:
18/455,173 →
Organic Compositions to Treat Beta-Catenin-Related Diseases
Application:
18/404,338 →
Organic Compositions to Treat Beta-Catenin-Related Diseases
Application:
18/746,668 →
Organic Compositions to Treat Kras-Related Diseases
Application:
18/472,469 →
Organic Compositions to Treat Kras-Related Diseases
Application:
18/441,085 →
Organic Compositions to Treat Kras-Related Diseases
Application:
18/749,208 →
Organic Compositions to Treat EPAS1-Related Diseases
Organic Compositions to Treat EPAS1 - Related Diseases
Organic Compositions to Treat EPAS1-Related Diseases
Organic Compositions to Treat HSF1-Related Diseases
Organic Compositions to Treat APOC3-Related Diseases
Organic Compositions to Treat APOC3-Related Diseases
Methods of Treatment of Cancer with Reduced Ubb Expression
Rnai-Mediated Inhibition of Frizzled Related Protein-1 for Treatment of Glaucoma
Rnai-Mediated Inhibition of Frizzled Related Protein-1 for Treatment of Glaucoma
Rnai-Mediated Inhibition of Frizzled Related Protein-1 for Treatment of Glaucoma
Rnai-Mediated Inhibition of Frizzled Related Protein-1 for Treatment of Glaucoma
Patent:
9,550,994 →
Application:
14/692,402 →
Rnai-Mediated Inhibition of H1F1A for Treatment of Ocular Angiogenesis
Rnai-Mediated Inhibition of HIF1A for Treatment of Ocular Angiogenesis
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
RNAi-Mediated Inhibition of Phosphodiesterase Type 4 for Treatment of cAMP-Related Ocular Disorders
Patent:
8,673,873 →
Application:
12/580,663 →
RNAi-MEDIATED INHIBITION OF PHOSPHODIESTERASE TYPE 4 FOR TREATMENT OF cAMP-RELATED OCULAR DISORDERS
Rnai-Mediated Inhibition of Phosphodiesterase Type 4 for Treatment of Camp-Related Ocular Disorders
Rnai-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions
Rnai-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions
RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
Rnai-Mediated Inhibition of Histamine Receptor H1-Related Conditions
Rnai-Mediated Inhibition of Histamine Receptor H1-Related Conditions
RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions
RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions
Rnai-Mediated Inhibition of Histamine Receptor H1-Related Conditions
Rnai-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions
RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions
RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS
RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis
Transferrin/Transferrin Receptor-Mediated Sirna Delivery
Patent:
7,973,019 →
Application:
12/244,027 →
TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
Transferrin/Transferrin Receptor-Mediated Sirna Delivery
Low Density Lipoprotein Receptor-Mediated Sirna Delivery
Low Density Lipoprotein Receptor-Mediated Sirna Delivery
LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
Rnai-Related Inhibition of Tnfa Signaling Pathway for Treatment of Glaucoma
Interfering Rna Delivery System and Uses Thereof
Interfering Rna Delivery System and Uses Thereof
Interfering Rna Delivery System and Uses Thereof
Interfering Rna Delivery System and Uses Thereof
RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS
RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS
RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS
Interfering Rna Delivery System and Uses Thereof
Interfering Rna Delivery System and Uses Thereof
Rnai Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use
PCT:
PCT/US2022/030969 ↗
RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
PCT:
PCT/US2021/024299 ↗
Rnai Agents for Inhibiting Expression of Matrix Metalloproteinase 7(MMP7), Compositions Thereof, and Methods of Use
PCT:
PCT/US2022/078498 ↗
Rnai Agents for Inhibiting Expression of DUX4, Compositions Thereof, and Methods Of
PCT:
PCT/US2021/049871 ↗
Methods for the Treatment of APOC3-Related Diseases and Disorders
PCT:
PCT/US2020/044879 ↗
Skeletal Muscle Delivery Platforms and Methods of Use
PCT:
PCT/US2021/049874 ↗
Lipid Conjugates for the Delivery of Therapeutic Agents
PCT:
PCT/US2021/049880 ↗
Rnai Agents for Inhibiting Expression of Receptor for Advanced Glycation End-Products, Compositions Thereof, and Methods of Use
PCT:
PCT/US2022/023813 ↗
Skeletal Muscle Delivery Platforms and Methods of Use
PCT:
PCT/US2021/049889 ↗
Methods for the Reduction of Z-Aat Protein Levels
PCT:
PCT/US2021/050247 ↗
Integrin Targeting Ligands and Uses Thereof
PCT:
PCT/US2021/049905 ↗
Rnai Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of Use
PCT:
PCT/US2023/077878 ↗
Rnai Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use
PCT:
PCT/US2023/068438 ↗
Rnai Agents for Inhibiting Expression of Xanthine Dehydrogenase (Xdh), Pharmaceutical Compositions Thereof, and Methods of Use
PCT:
PCT/US2022/034102 ↗
Rnai Agents for Inhibiting Expression of Ataxin-2 (ATXN2), Compositions Thereof, and Methods of Use
PCT:
PCT/US2024/020125 ↗
Rnai Agents for Inhibiting Expression of Coronavirus (Cov) Viral Genomes, Compositions Thereof, and Methods of Use
PCT:
PCT/US2023/061856 ↗
Treatment of a Non-Alcoholic Fatty Liver Disease
PCT:
PCT/US2023/065487 ↗
Subcutaneous Delivery of Rnai Agents for Inhibiting Expression of Receptor for Advanced Glycation End-Products
PCT:
PCT/US2023/064778 ↗
Lipid Conjugates for the Delivery of Therapeutic Agents to Cns Tissue
PCT:
PCT/US2023/068439 ↗
Rnai Agents for Inhibiting Expression of Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Pharmaceutical Compositions Thereof, and Methods of Use
PCT:
PCT/US2024/017797 ↗
Methods for the Treatment of ANGPTL3-Related Diseases and Disorders
PCT:
PCT/US2023/072573 ↗
Rnai Agents for Inhibiting Expression of DM1 Protein Kinase (Dmpk) Compositions Thereof, and Methods of Use
PCT:
PCT/US2023/077179 ↗
Lipid Conjugates for the Delivery of Therapeutic Agents to Adipose Tissue
PCT:
PCT/US2024/010584 ↗
Rnai Agents for Inhibiting Influenza a Viral Gene Expression, Compositions Thereof, and Methods of Use
PCT:
PCT/US2024/011462 ↗
Rnai Agents for Inhibiting Expression of Mitochondrial Amidoxime Reducing Component 1 (MARC1), Pharmaceutical Compositions Thereof, and Methods of Use
PCT:
PCT/US2024/020222 ↗
Rnai Agents for Inhibiting Expression of Complement Factor B (Cfb), Pharmaceutical Compositions Thereof, and Methods of Use
PCT:
PCT/US2024/020691 ↗
Belt Reactor Manufacturing Process for Oligomer Synthesis
PCT:
PCT/US2024/013817 ↗
Optimized Rnai Agents for Inhibiting Expression of Coronavirus (Cov) Viral Genomes, Compositions Thereof, and Methods of Use
PCT:
PCT/US2024/014020 ↗
Hepatic Delivery Platforms for Multimeric Rnai Agent Conjugates and Methods of Use Thereof
PCT:
PCT/US2024/031750 ↗
Rnai Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (Tslp), Compositions Thereof, and Methods of Use
PCT:
PCT/US2024/015753 ↗
Metabolically Stabilized Carbohydrate Targeting Ligands for Oligonucleotide Conjugates
PCT:
PCT/US2024/031757 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Oct 10, 2013
From: HAGSTROM, JAMES E; WOLFF, JON A; LEWIS, DAVID L; ROZEMA, DAVID B
To: ARROWHEAD MADISON INC.
Reel/Frame 031379/0489 →
Change of Name
Feb 26, 2014
From: ROCHE MADISON INC.
To: ARROWHEAD MADISON INC.
Reel/Frame 032302/0843 →
Assignment of Assignor's Interest
Mar 4, 2014
From: ROZEMA, DAVID B; LEWIS, DAVID L; WAKEFIELD, DARREN H; HOFFMANN, TORSTEN
To: ARROWHEAD MADISON INC.
Reel/Frame 032345/0457 →
Assignment of Assignor's Interest
Jan 14, 2015
From: ROZEMA, DAVID B; WOLFF, JON A; HAGSTROM, JAMES E; EKENA, KIRK
To: ARROWHEAD MADISON INC.
Reel/Frame 034704/0124 →
Assignment of Assignor's Interest
Apr 9, 2015
From: LEWIS, DAVID L; ROZEMA, DAVID B; WAKEFIELD, DARREN H
To: ARROWHEAD MADISON INC.
Reel/Frame 035367/0326 →
Assignment of Assignor's Interest
Jun 27, 2016
From: LEWIS, DAVID L.; WAKEFIELD, DARREN H.; ROZEMA, DAVID B.; HOFFMANN, TORSTEN
To: ARROWHEAD MADISON INC.
Reel/Frame 039013/0542 →
Assignment of Assignor's Interest
Jul 26, 2016
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 039253/0123 →
Assignment of Assignor's Interest
Feb 28, 2017
From: HOFFMANN-LA ROCHE INC.
To: ARROWHEAD RESEARCH CORPORATION
Reel/Frame 041397/0071 →
Change of Name
Feb 28, 2017
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 041829/0290 →
Assignment of Assignor's Interest
Feb 28, 2017
From: BOYLAN, JOHN FREDERICK; BRAMLAGE, BIRGIT; HOSSBACH, MARKUS; REIDHAAR-OLSON, JOHN
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 041829/0164 →
Assignment of Assignor's Interest
Feb 28, 2017
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 041829/0162 →
Assignment of Assignor's Interest
Mar 12, 2018
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 045177/0355 →
Assignment of Assignor's Interest
Mar 19, 2018
From: HOFFMANN-LA ROCHE INC.
To: ARROWHEAD RESEARCH CORPORATION
Reel/Frame 045275/0541 →
Assignment of Assignor's Interest
Mar 19, 2018
From: BOYLAN, JOHN FREDERICK; BRAMLAGE, BIRGIT; HOSSBACH, MARKUS; REIDHAAR-OLSON, JOHN
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 045639/0859 →
Assignment of Assignor's Interest
Mar 19, 2018
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 045639/0888 →
Change of Name
Mar 19, 2018
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 045639/0914 →
Assignment of Assignor's Interest
Aug 8, 2024
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068227/0571 →
Assignment of Assignor's Interest
Aug 8, 2024
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068227/0385 →
Assignment of Assignor's Interest
Aug 8, 2024
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068228/0290 →
Assignment of Assignor's Interest
Aug 8, 2024
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068228/0278 →
Assignment of Assignor's Interest
Aug 8, 2024
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068228/0160 →
Assignment of Assignor's Interest
Aug 8, 2024
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068227/0973 →
Assignment of Assignor's Interest
Aug 8, 2024
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068227/0932 →
Assignment of Assignor's Interest
Aug 8, 2024
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068227/0904 →
Assignment of Assignor's Interest
Aug 8, 2024
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068227/0797 →